Caladrius Biosciences Reports Publication of Two-Year Results from Phase 1 Trial of Type 1 Diabetes Candidate
December 01, 2015 at 07:32 AM EST
Caladrius Biosciences, Inc. ("Caladrius" or the "Company") (NASDAQ: CLBS), a cell therapy company combining an industry-leading external ...